The latest quarterly earnings report from healthcare equipment company TransMedics Group (NASDAQ: TMDX) brought a great many bulls back to the stock. On the back of convincing beats on analyst estimates plus strong guidance, the share price was up nearly 18% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence .
On Wednesday, TransMedics published its fourth-quarter and full-year 2022 results. For the former period, it booked $31.4 million in revenue, which was a mighty 225% higher year over year. Compounding that, the niche healthcare company significantly trimmed its net loss -- this came in at $6.7 million, or $0.21 per share, a notable improvement over Q4 2021's $12.7 million shortfall.
Both headline figures were far better than analysts expected. Collectively, prognosticators following TransMedics stock were anticipating slightly under $24.5 million in revenue and a $0.30-per-share net loss.
For further details see:
Why TransMedics Stock Was a Big Star This Week